Results 231 to 240 of about 4,835,435 (314)

Downregulation of sST2, a decoy receptor for interleukin‐33, enhances subcutaneous tumor growth in murine pancreatic cancer cells

open access: yesFEBS Open Bio, EarlyView.
Subcutaneous implantation of murine Panc02 pancreatic cancer cells depleted of sST2, a soluble decoy receptor for the proinflammatory interleukin‐33 (IL‐33), leads to a decreased number of GLUT4‐positive cancer‐associated adipocytes, reduced levels of the anti‐inflammatory molecule adiponectin, increased phosphorylation of IκBα, elevated Cxcl3 ...
Miho Akimoto   +5 more
wiley   +1 more source

Cis‐unsaturated sphingolipids support growth of sphingoid base‐deficient yeast but impair plasma membrane integrity

open access: yesFEBS Open Bio, EarlyView.
Sphingoid base structures, the sphingolipid backbones, vary among species. We established yeast cells in which the native sphingoid base was replaced with plant‐type bases containing cis or trans double bonds. This is, to our knowledge, the first eukaryotic model mostly composed of sphingolipids containing cis‐unsaturated sphingoid base, providing a ...
Takashi Higuchi   +5 more
wiley   +1 more source

Can adults automatically process and translate between numerical representations? [PDF]

open access: yesR Soc Open Sci
Xenidou-Dervou I   +4 more
europepmc   +1 more source

Most autophagic cell death studies lack evidence of causality

open access: yesFEBS Open Bio, EarlyView.
Of 104 studies claiming autophagic cell death (ACD), only 13 demonstrated both causality and exclusion of apoptosis to confirm true ACD. Most studies relied on correlation‐level data or measured autophagy in isolation, revealing pervasive methodological shortcomings.
Ali Burak Özkaya, Yasmin Ghaseminejad
wiley   +1 more source

Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The characteristics and utility of composite progression independent of relapse activity (cPIRA; worsening on the Expanded Disability Status Scale [EDSS], or 9‐Hole Peg Test, or Timed 25‐Foot Walk Test) were evaluated as an endpoint in relapsing multiple sclerosis (RMS) trials using the ENSEMBLE (NCT03085810) and pooled OPERA I/II ...
Ludwig Kappos   +11 more
wiley   +1 more source

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial. [PDF]

open access: yesSignal Transduct Target Ther
Zhao C   +59 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy